tert-butyl 3-[(tert-butoxycarbonyl)amino]-4-hydroxypyrrolidine-1-carboxylate | 203434-46-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl 3-[(tert-butoxycarbonyl)amino]-4-hydroxypyrrolidine-1-carboxylate
• 英文别名: 3-tert-Butoxycarbonylamino-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester；tert-butyl 3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]pyrrolidine-1-carboxylate
• CAS: 203434-46-2
• 化学式: C₁₄H₂₆N₂O₅
• 分子量: 302.371
• InChiKey: FQEKHGSKXWNVPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  88.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-[(tert-butoxycarbonyl)amino]-4-hydroxypyrrolidine-1-carboxylate 以81的产率得到4-methoxy-N-methylpyrrolidin-3-amine; bis(para-toluene sulfonate)
  参考文献：
  名称：

  Tetrahedron: Asymmetry 2001, 12, 1793-1799

  摘要：

  DOI：
• 作为产物：
  描述：

  N-Boc-3-吡咯啉 在 氨 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 31.0h， 生成 tert-butyl 3-[(tert-butoxycarbonyl)amino]-4-hydroxypyrrolidine-1-carboxylate
  参考文献：
  名称：

  FUSED HETEROCYCLIC COMPOUND

  摘要：

  本发明涉及具有化学式1的融合杂环化合物，其作为血小板聚集抑制剂有用，以及制备该化合物的方法，以及包含该化合物的用于抑制血小板聚集的药物组合物。

  公开号：

  US20110166121A1

文献信息

• FUSED HETEROCYCLIC COMPOUND
  申请人：Lee Chang Seok

  公开号：US20110166121A1

  公开（公告）日：2011-07-07

  The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.

  本发明涉及具有化学式1的融合杂环化合物，其作为血小板聚集抑制剂有用，以及制备该化合物的方法，以及包含该化合物的用于抑制血小板聚集的药物组合物。
• Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
  申请人：Biftu Tesfaye

  公开号：US20090270467A1

  公开（公告）日：2009-10-29

  The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式（I）的新型取代氨基环己烷，其是二肽基肽酶-IV酶的抑制剂，并且对于涉及二肽基肽酶-IV酶的疾病的治疗或预防，例如糖尿病，特别是2型糖尿病，具有用途。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗涉及二肽基肽酶-IV酶的疾病中的使用。
• Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07750034B2

  公开（公告）日：2010-07-06

  The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种结构式为（I）的新型取代氨基环己烷，其为二肽基肽酶-IV酶的抑制剂，可用于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗二肽基肽酶-IV酶参与的疾病中的用途。
• [EN] CYCLOAMINO DERIVATIVES AS GPR119 AGONISTS<br/>[FR] DÉRIVÉS DE CYCLOAMINO COMME ANTAGONISTES DU GPR119
  申请人：PROSIDION LTD

  公开号：WO2011147951A8

  公开（公告）日：2012-03-15
• Methyloxime-substituted aminopyrrolidine: A new surrogate for 7-basic group of quinolone
  作者：ChangYong Hong、Young Kwan Kim、Yong Hee Lee、Jin Hwan Kwak

  DOI：10.1016/s0960-894x(97)10222-0

  日期：1998.2

  Novel fluoroquinolones containing oxime functionalized aminopyrrolidines have been synthesized. They were found to possess potent antibacterial activities against both Gram-negative and Gram-positive organisms, including methicillin resistant Staphylococcus aureus (MRSA). Among these compounds, LB20277 (compound 12) showed the most favorable in vivo efficacy and pharmacokinetic profile in animals. Based on these promising results, LB20277 was selected as a candidate for further evaluation. (C) 1998 Elsevier Science Ltd. All rights reserved.